173 related articles for article (PubMed ID: 37090442)
1. Investigating potential confounding by indication when considering the association between proton pump inhibitor use, infection, hepatic encephalopathy and mortality in hospitalised decompensated cirrhosis: a post-hoc analysis of the ATTIRE trial.
China L; Tittanegro T; Crocombe D; Forrest E; Kallis Y; Ryder SD; Wright G; Freemantle N; O'Brien A
EClinicalMedicine; 2023 Apr; 58():101924. PubMed ID: 37090442
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
[TBL] [Abstract][Full Text] [Related]
3. Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: Data from the ATTIRE trial.
Tittanegro T; China L; Forrest E; Kallis Y; Ryder SD; Wright G; Freemantle N; O'Brien A
EClinicalMedicine; 2023 Jan; 55():101716. PubMed ID: 36407574
[TBL] [Abstract][Full Text] [Related]
4. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding.
Hung TH; Lee HF; Tseng CW; Tsai CC; Tsai CC
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):353-359. PubMed ID: 29551615
[TBL] [Abstract][Full Text] [Related]
5. Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial.
Wehmeyer MH; Horvatits T; Buchholz A; Krause L; Walter S; Zapf A; Lohse AW; Kluwe J;
Trials; 2022 Apr; 23(1):302. PubMed ID: 35414106
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Summereder C; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
PLoS One; 2014; 9(11):e110503. PubMed ID: 25369194
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients.
Fasullo M; Rau P; Liu DQ; Holzwanger E; Mathew JP; Guilarte-Walker Y; Szabo G
World J Hepatol; 2019 Jun; 11(6):522-530. PubMed ID: 31293720
[TBL] [Abstract][Full Text] [Related]
8. Proton Pump Inhibitors Use and Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Retrospective Cohort Analysis.
Dahabra L; Kreidieh M; Abureesh M; Abou Yassine A; Deeb L
Gastroenterology Res; 2022 Aug; 15(4):180-187. PubMed ID: 36128183
[TBL] [Abstract][Full Text] [Related]
9. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
Dam G; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Oct; 64(4):1265-72. PubMed ID: 27474889
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial.
China L; Skene SS; Bennett K; Shabir Z; Hamilton R; Bevan S; Chandler T; Maini AA; Becares N; Gilroy D; Forrest EH; O'Brien A
BMJ Open; 2018 Oct; 8(10):e023754. PubMed ID: 30344180
[TBL] [Abstract][Full Text] [Related]
13. Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding.
Keyvani L; Murthy S; Leeson S; Targownik LE
Aliment Pharmacol Ther; 2006 Oct; 24(8):1247-55. PubMed ID: 17014584
[TBL] [Abstract][Full Text] [Related]
14. Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis.
Wang J; Wu Y; Bi Q; Zheng X; Zhang J; Huang W
Hepatol Int; 2020 May; 14(3):385-398. PubMed ID: 31912308
[TBL] [Abstract][Full Text] [Related]
15. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan.
Sakamaki A; Kamimura K; Yokoo T; Osaki A; Yoshikawa S; Arao Y; Setsu T; Kamimura H; Waguri N; Takeuchi M; Funakoshi K; Terai S
Medicine (Baltimore); 2021 Aug; 100(32):e26902. PubMed ID: 34397919
[TBL] [Abstract][Full Text] [Related]
16. Effect of Proton Pump Inhibitors on Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis.
Hung TH; Tseng CW; Lee HF; Tsai CC; Tsai CC
Ann Hepatol; 2018 Oct; 17(6):933-939. PubMed ID: 30600287
[TBL] [Abstract][Full Text] [Related]
17. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis.
Janka T; Tornai T; Borbély B; Tornai D; Altorjay I; Papp M; Vitális Z
Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):257-264. PubMed ID: 31464790
[TBL] [Abstract][Full Text] [Related]
18. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Proton Pump Inhibitor Therapy in the Prevention of Bleeding After Prophylactic Endoscopic Variceal Band Ligation.
Khawaja I; Babar M; Awan SA; Shaikh AJ; Abbasi AA
Cureus; 2023 Jan; 15(1):e33932. PubMed ID: 36819375
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitor Use and Complications of Cirrhosis Are Linked With Distinct Gut Microbial Bacteriophage and Eukaryotic Viral-Like Particle Signatures in Cirrhosis.
Peña Rodríguez M; Fagan A; Sikaroodi M; Gillevet PM; Bajaj JS
Clin Transl Gastroenterol; 2024 Feb; 15(2):e00659. PubMed ID: 37937851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
